Infection and Drug Resistance

metrics 2024

Illuminating the path to effective therapeutic interventions.

Introduction

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Metrics 2024

SCIMAGO Journal Rank0.74
Journal Impact Factor2.90
Journal Impact Factor (5 years)3.60
H-Index65
Journal IF Without Self2.90
Eigen Factor0.01
Normal Eigen Factor3.16
Influence0.75
Immediacy Index0.60
Cited Half Life3.40
Citing Half Life5.50
JCI0.76
Total Documents3325
WOS Total Citations9759
SCIMAGO Total Citations23528
SCIMAGO SELF Citations1260
Scopus Journal Rank0.74
Cites / Document (2 Years)2.87
Cites / Document (3 Years)3.34
Cites / Document (4 Years)3.61

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #88/272
Percentile 67.65
Quartile Q2
Infectious Diseases in Medicine
Rank #126/344
Percentile 63.37
Quartile Q2
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #134/313
Percentile 57.19
Quartile Q2

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 58/132
Percentile 56.40
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 147/354
Percentile 58.60
Quartile Q2

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 50/132
Percentile 62.12
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 136/354
Percentile 61.58
Quartile Q2

Quartile History

Similar Journals

Gut Pathogens

Connecting the Dots Between Gut Health and Infectious Threats
Publisher: BMCISSN: 1757-4749Frequency: 1 issue/year

Gut Pathogens, published by BMC in the United Kingdom, is a premier open-access journal focusing on the intersection of gut health and infectious diseases. With its impact firmly established since its inception in 2009, the journal has earned impressive rankings, including Q1 in renowned categories such as Gastroenterology, Infectious Diseases, Microbiology, and Parasitology, while maintaining a strong presence in Virology. The journal serves as a vital resource for researchers, professionals, and students interested in the intricate relationships between gut microbiota and pathogenic organisms, offering insights that drive advancements in treatment and prevention strategies. By providing unrestricted access to high-quality research, Gut Pathogens fosters a collaborative environment, encouraging the dissemination of knowledge and innovation within the field. The journal publishes original research, reviews, and case studies, all designed to address contemporary challenges in gut health, ultimately aiming to improve patient outcomes and public health worldwide.

Microbial Drug Resistance

Elevating Research on the Frontlines of Drug Resistance
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Journal of Global Antimicrobial Resistance

Empowering research to combat resistance worldwide.
Publisher: ELSEVIER SCI LTDISSN: 2213-7165Frequency: 4 issues/year

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

JOURNAL OF CHEMOTHERAPY

Pioneering Knowledge in Chemotherapy and Beyond
Publisher: TAYLOR & FRANCIS LTDISSN: 1120-009XFrequency: 6 issues/year

Journal of Chemotherapy is a distinguished peer-reviewed academic journal published by Taylor & Francis Ltd, focusing on the dynamic fields of infectious diseases, oncology, and pharmacology. With its ISSN 1120-009X and E-ISSN 1973-9478, this journal has been at the forefront of chemotherapy research since its inception in 1989 and continues to play a vital role in advancing medical science through rigorous studies and reviews. It currently holds a respectable position in various Scopus categories, ranked Q3 in several important disciplines, reflecting its commitment to providing quality research. Although it operates under a subscription model, Journal of Chemotherapy remains a crucial resource for practitioners and academics alike, facilitating knowledge exchange and innovation in the treatment of diseases through chemotherapy. With access to the latest findings and therapeutic advancements, this journal is a must-read for researchers, medical professionals, and students seeking to enhance their understanding of emerging trends in chemotherapy.

JAPANESE JOURNAL OF INFECTIOUS DISEASES

Empowering professionals with cutting-edge research and discoveries.
Publisher: NATL INST INFECTIOUS DISEASESISSN: 1344-6304Frequency: 6 issues/year

The Japanese Journal of Infectious Diseases, published by the National Institute of Infectious Diseases in Japan, serves as a vital platform for researchers, clinicians, and public health professionals committed to advancing the field of infectious disease science. With an ISSN of 1344-6304 and an E-ISSN of 1884-2836, this journal has maintained its academic rigor since its inception in 1961 and continues to contribute significantly to the global understanding of infectious diseases. The journal holds a Q3 ranking in the categories of Infectious Diseases, Miscellaneous Medicine, and Medical Microbiology as of 2023, reflecting its important role in disseminating impactful research. With many articles available through Open Access, it ensures wide accessibility to the latest discoveries and insights. Researchers can expect to find high-quality studies that address critical challenges in the control and prevention of infectious diseases, making this journal an essential resource for anyone engaging in this critical field.

Expert Review of Anti-Infective Therapy

Elevating Standards in Anti-Infective Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-7210Frequency: 12 issues/year

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

INFECTION

Uncovering Breakthroughs in Microbiology and Medicine
Publisher: SPRINGER HEIDELBERGISSN: 0300-8126Frequency: 6 issues/year

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

CURRENT HIV RESEARCH

Advancing the Frontiers of HIV Knowledge
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-162XFrequency: 6 issues/year

Current HIV Research is a pivotal journal dedicated to the latest advancements in the field of HIV research, published by Bentham Science Publishers Ltd. With a commitment to disseminating high-quality research, this journal serves as a critical resource for researchers, healthcare professionals, and students interested in infectious diseases and virology. The journal has an ISSN of 1570-162X and an E-ISSN of 1873-4251, reflecting its commitment to contemporary digital scholarship. Given its publication history spanning from 2003 to 2024, the journal has continually provided insights and peer-reviewed articles that foster knowledge and innovation in HIV research. Although it currently holds a Q3 ranking in Infectious Diseases and a Q4 ranking in Virology, these rankings underscore its importance as an emerging platform for critical research dialogue. Despite not being an Open Access journal, 'Current HIV Research' ensures that cutting-edge studies reach relevant practitioners and contribute to ongoing discourse in the medical community. By fostering an informed approach to HIV and its implications, this journal is an invaluable asset to those committed to advancing their expertise in this crucial area of health science.

Infectious Diseases and Clinical Microbiology

Fostering collaboration in the fight against infectious agents.
Publisher: DOC DESIGN INFORMATICS CO LTDISSN: 2667-646XFrequency: 4 issues/year

Infectious Diseases and Clinical Microbiology is a pivotal journal dedicated to advancing our understanding of infectious diseases through rigorous scientific research and clinical practices. Published by DOC DESIGN INFORMATICS CO LTD, this journal serves as a vital platform for researchers, healthcare professionals, and students keen on enhancing their knowledge of microbiological sciences and the clinical implications of infectious agents. With an ISSN of 2667-646X, it aims to disseminate significant findings in the field, enriching the scholarly dialogue surrounding infectious diseases. While currently operating under a traditional access model, the journal encourages global collaboration and knowledge sharing, striving to make a meaningful impact in tackling the challenges posed by infectious diseases. Its content aims to bridge the gap between laboratory research and clinical application, making it an essential resource in the contemporary landscape of global health.

Infection and Chemotherapy

Exploring Innovations in Infectious Disease Treatment
Publisher: KOREAN SOC ANTIMICROBIAL THERAPYISSN: 2093-2340Frequency: 4 issues/year

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.